S-nitrosoglutathione inhalation - Alpine Immune Sciences

Drug Profile

S-nitrosoglutathione inhalation - Alpine Immune Sciences

Alternative Names: GSNO; N 30-201; S-nitroso-GSH; S-nitroso-L-glutathione

Latest Information Update: 26 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NitroMed
  • Developer Nivalis Therapeutics
  • Class Antiplatelets; Bronchodilators; Oligopeptides; S-nitrosothiols; Small molecules
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis

Most Recent Events

  • 25 Jul 2017 Alpine Immune Sciences has merged with Nivalis Therapeutics forming Alpine Immune Sciences
  • 01 Jul 2010 No development reported - Phase-I for Asthma in USA (Inhalation)
  • 01 Jul 2010 No development reported - Phase-I for Chronic obstructive pulmonary disease in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top